Market closed
Pharvaris/$PHVS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Pharvaris
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.
Ticker
$PHVS
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
108
Website
Pharvaris Metrics
BasicAdvanced
$748M
-
-$2.82
-2.84
-
Price and volume
Market cap
$748M
Beta
-2.84
52-week high
$25.50
52-week low
$11.51
Average daily volume
35K
Financial strength
Current ratio
12.597
Quick ratio
12.347
Long term debt to equity
0.239
Total debt to equity
0.322
Management effectiveness
Return on assets (TTM)
-26.39%
Return on equity (TTM)
-41.18%
Valuation
Price to book
2.79
Price to tangible book (TTM)
2.79
Price to free cash flow (TTM)
-5.405
Growth
Earnings per share change (TTM)
-5.44%
3-year earnings per share growth (CAGR)
20.93%
What the Analysts think about Pharvaris
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Pharvaris stock.
Pharvaris Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Pharvaris Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Pharvaris News
AllArticlesVideos
Pharvaris Announces Orphan Designation Granted to Deucrictibant by the European Commission
GlobeNewsWire·2 weeks ago
Pharvaris Presents Long-Term Clinical Data of Deucrictibant for the Prevention and Treatment of HAE Attacks at the 2025 AAAAI/WAO Joint Congress
GlobeNewsWire·1 month ago
Pharvaris to Participate in the Leerink Partners Global Healthcare Conference 2025
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Pharvaris stock?
Pharvaris (PHVS) has a market cap of $748M as of April 18, 2025.
What is the P/E ratio for Pharvaris stock?
The price to earnings (P/E) ratio for Pharvaris (PHVS) stock is 0 as of April 18, 2025.
Does Pharvaris stock pay dividends?
No, Pharvaris (PHVS) stock does not pay dividends to its shareholders as of April 18, 2025.
When is the next Pharvaris dividend payment date?
Pharvaris (PHVS) stock does not pay dividends to its shareholders.
What is the beta indicator for Pharvaris?
Pharvaris (PHVS) has a beta rating of -2.84. This means that it has an inverse relation to market volatility.